COV.v: I haven't made any money on COV because I haven't sold any.....and I'm actually bidding on more down here. I missed a good opportunity to sell last summer; but believe in the long-term prospects here particularly because the company is sitting on a healthy amount of cash and running their core operations at near break even, and seams to be on the cusp of a healthy new growth trend.
It's taken a while, but last quarter showed a significant increase in wound care sales and overall revenue. The company attributes most of the growth to a new distributor in the middle east and expects continued growth from expansion of it's product line next year.
That's not to mention the potential for further licensing agreements and partnerships for their Intellectual Property portfolio for infection control products and technology.
Liquidity is anemic here, but that's part of the opportunity I see here, as I believe I could be early in a very low OS/low float company with truly game changing products and technology in their IP portfolio.
| Fiscal Quarter | Wound Care Sales | Specialized Medical
Device Coatings | Licensing Fees | Total Revenue | Earnings | | | | | | | | | Q2/2015 | $1,742,672 | $312,519 | $125,085 | $2,180,276 | $264,340 | | Q1/2015 | $767,091 | $454,607 | $114,987 | $1,336,685 | ($229,820) | | Q4/2014 | $1,099,855 | - | $106,304 | $1,206,159 | ($909,705) | | Q3/2014 | $1,119,559 | $14,100 | $157,719 | $1,291,378 | ($240,156) | | Q2/2014 | $1,400,065 | $462,000 | $179,526 | $2,041,591 | $431,211 | | Q1/2014 | $733,590 | - | $3,788,611 | $4,522,201 | $3,120,419 | | Q4/2013 | $1,352,855 | $71,092 | $130,706 | $1,543,019 | $125,319 | | Q3/2013 | $1,411,220 | - | $66,412 | $1,477,632 | $234,826 | | Q2/2013 | $478,371 | - | $51,482 | $535,224 | ($558,831) | | Q1/2013 | $520,523 | - | $51,482 | $572,005 | ($794,481)
|
|
